Biostage reports Q3 net loss of $1.1M ($0.10/share); cash runway into Q2 2023

Harvard Apparatus Regenerative Technology, Inc.

2022-Q3 EPS reported -$0.42

Net loss $1.1M for Q3 2022 vs $0.8M in Q3 2021; EPS -$0.10 vs -$0.08.
Operating cash $3.0M as of Sept 30, 2022; cash used in ops $3.4M in first 9 months.
Expects cash to fund operations into Q2 2023.
Received U.S. patent for cellularized patch-based scaffolds (Biostage Tissue Patch) on Oct 25, 2022.
Appointed Joseph Damasio as CFO on Aug 8, 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harvard Apparatus Regenerative Technology, Inc. reported the three months ended September 30, 2022 results: net income a net loss of approximately $1.1 million, EPS $0.10 per share.

Period: the three months ended September 30, 2022
Net income: a net loss of approximately $1.1 million
EPS: $0.10 per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, the Company reported a net loss of approximately $1.1 million, or $0.10 per share, compared to a net loss of $0.8 million, or $0.08 per share, for the three months ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

Harvard Apparatus Regenerative Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001563665-22-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.